Xerostomia: Causes and treatment

Consultant Pharmacist

Volumn 22, Issue 12, 2007, Pages 985-992

  Wick, Jeannette Y ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Autoimmune disease; Dental care; Elderly; Mucosal moisturizers; Xerostomia

Indexed keywords

ALPHA INTERFERON; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; CEVIMILINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; DIURETIC AGENT; GLYCERYL TRINITRATE; PILOCARPINE; TRANQUILIZER; UNCLASSIFIED DRUG;

ANGINA PECTORIS; AUTOIMMUNE DISEASE; BEDTIME DOSAGE; BONE MARROW TRANSPLANTATION; CLINICAL FEATURE; CLINICAL TRIAL; DENTAL HEALTH; DENTIST; DIARRHEA; DIGESTION; DISEASE COURSE; DISEASE EXACERBATION; FLUSHING; HUMAN; NAUSEA; POLYURIA; REVIEW; RHINITIS; SALIVATION; SELF REPORT; SIDE EFFECT; SWEATING; TOOTH DISEASE; WEIGHT REDUCTION; XEROSTOMIA;

EID: 37349041724     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2007.985     Document Type: Review

References (41)

1. Dubnar R, Sessle BJ, Storey AT. The Neural Basis of Oral and Facial Function. New York, NY: Plenum Press; 1978:391-3.
2. Neville BW, Damm DD, Allen CM et al. Oral and Maxillofacial Pathology. 2nd ed. Philadelphia, PA: W.B. Saunders; 2002:398-404.
3. Fox PC, van der Ven PF, Sonies BC et al. Xerostomia: evaluation of a symptom with increasing significance. JADA 1985;110:519-25.
4. Sreebny LM, Valdini A. Xerostomia: a neglected symptom. Arch Intern Med 1987;147:1333-7.
5. Hochberg MC, Tielsch J, Munoz B et al. Prevalence of symptoms of dry mouth and their relationship to saliva production in community dwelling elderly: the SEE project - Salisbury Eye Evaluation. J Rheumatol 1998;25:486-91.
6. Gilbert GH, Heft MW, Duncan RP. Mouth dryness as reported by older Floridians. Community Dent Oral Epidemiol 1993;21:390-7.
7. Billings RJ, Proskin HM, Moss ME. Xerostomia and associated factors in a community-dwelling adult population. Community Dent Oral Epidemiol 1996;24:312-6.
8. Nederfors T, Isaksson R, Mornstad H et al. Prevalence of perceived symptoms of dry mouth in an adult Swedish population: relation to age, sex and pharmacotherapy. Community Dent Oral Epidemiol 1997;25:211-6.
9. Orellana MF, Lagravere MO, Boychuk DG et al. Prevalence of xerostomia in population-based samples: a systematic review. J Public Health Dent 2006;66:152-8.
10. Dawes C. Physiological factors affecting salivary flow rate, oral sugar clearance, and the sensation of dry mouth in man. J Dent Res 1987;66:648-53.
11. Ghezzi EM, Lange LA, Ship JA. Determination of variation of stimulated salivary flow rates. J Dent Res 2000;79:1874-8.
12. Ship J, Fox PC, Baum BJ. How much saliva is enough? 'Normal' function defined. JADA 1991;122:63-9.
13. International Dental Federation. Working Group 10 of the Commission on Oral Health, Research and Epidemiology (CORE). Saliva: its role in health and disease. Int Dent J 1992;42 4 suppl 2:287-304.
14. Wallace DJ, ed. The new Sjögren's Syndrome Handbook. 3rd edition. London, UK: Oxford University Press; 2004.
15. Atkinson JC, Yeh C, Oppenheim FG et al. Elevation of salivary antimicrobial proteins following HIV-1 infection. J Acquir Immune Defic Syndr 1990;3:41-8.
16. Guggenheimer J, Moore PA, Rossie K et al. Insulin-dependent diabetes mellitus and oral soft tissue pathologies, part II: prevalence and characteristics of Candida and candidal lesions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;89:570-6.
17. Moore PA, Guggenheimer J, Etzel KR et al. Type 1 diabetes mellitus, xerostomia, and salivary flow rates. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;92:281-91.
18. Guggenheimer J, Moore PA. Xerostomia: etiology, recognition and treatment. J Am Dent Assoc 2003;134:61-9.
19. Ship JA, Pillemer SR, Baum BJ. Xerostomia and the geriatric patient. J Am Geriatr Soc 2002;50:535-43.
20. Narhi TO, Meurman JH, Ainamo A. Xerostomia and hyposalivation: causes, consequences and treatment in the elderly. Drugs Aging 1999;15:103-16.
21. Sreebny LM. A useful source for the drug-dry mouth relationship. J Dent Educ 2004;68:6-7.
22. Cooper JS, Fu K, Marks J et al. Late effects of radiation in the head and neck region. Int J Radiat Oncol Biol Phys 1995;31:1141-64.
23. Valdez IH, Atkinson JC, Ship JA et al. Major salivary gland function in patients with radiation-induced xerostomia: flow rates and sialochemistry. Int J Radiat Oncol Biol Phys 1993;25:41-7.
24. Henson BS, Eisbruch A, D'Hondt E et al. Two-year longitudinal study of parotid salivary flow rates in head and neck cancer patients receiving unilateral neck parotid-sparing radiotherapy treatment. Oral Oncol 1999;35:234-41.
25. Chambers MS, Posner M, Jones CU et al. Cevimeline for the treatment of postirradiation xerostomia in patients with head and neck cancer. Int J Radiat Oncol Biol Phys 2007;68:1102-9.
26. Fox RI. Clinical features, pathogenesis, and treatment of Sjögren's syndrome. Curr Opin Rheumatol 1996;8:438-45.
27. Kordossis T, Paikos S, Aroni K et al. Prevalence of Sjögren's-like syndrome in a cohort of HIV-1-positive patients: descriptive pathology and immunology. Br J Rheumatol 1998;37:691-5.
28. Fox PC. Saliva and salivary gland alterations in HIV infection. JADA 1991;122:46-8.
29. Bergdahl M, Bergdahl J. Low unstimulated salivary flow and subjective oral dryness: association with medication, anxiety, depression, and stress. J Dent Res 2000;79:1652-8.
30. Anttila SS, Knuuttila ML, Sakki TK. Depressive symptoms as an underlying factor of the sensation of dry mouth. Psychosom Med 1998;60:215-8.
31. Ghezzi EM, Ship JA. Systemic diseases and their treatments in the elderly: impact on oral health. J Public Health Dent 2000;60:289-96.
32. Rhodus NL, Bereuter J. Clinical evaluation of a commercially available oral moisturizer in relieving signs and symptoms of xerostomia in postirradiation head and neck cancer patients and patients with Sjögren's syndrome. J Otolaryngol 2000;29:28-34.
33. Alves MB, Motta AC, Messina WC et al. Saliva substitute in xerostomic patients with primary Sjögren's syndrome: a single-blind trial. Quintessence Int 2004;35:392-6.
34. van der Reijden WA, van der Kwaak H, Vissink A et al. Treatment of xerostomia with polymer-based saliva substitutes in patients with Sjögren's syndrome. Arthritis Rheum 1996;39:57-63.
35. UK Department of Health. Oral health of people with dementia. Gerontology 2006;23 Suppl 1:3-32.
36. Daiichi Pharmaceutical Corporation. Evozac prescribing information. April 2005. Available at http://www.evoxac.com/prescribing_info.htm. Accessed August 8, 2007.
37. Novartis Pharma AG. Salagen complete prescribing information. Available at http://www.novartisophthalmics.com/hcp/products/salagen-si.jsp. Accessed August 8, 2007.
38. Khurshudian AV. A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjögren's syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003;95:38-44.
39. Shiozawa S, Tanaka Y, Shiozawa K. Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sjögren's syndrome. J Interferon Cytokine Res 1998;18:255-62.
40. Streckfus C, Bigler L, Navazesh M et al. Cytokine concentrations in stimulated whole saliva among patients with primary Sjögren's syndrome, secondary Sjögren's syndrome, and patients with primary Sjögren's syndrome receiving varying doses of interferon for symptomatic treatment of the condition: a preliminary study. Clin Oral Invest 2001;5:133-5.
41. Strietzel FP, Martin-Granizo R, Fedele S et al. Electrostimulating device in the management of xerostomia. Oral Dis 2007;13:206-13.